Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Northwell Health and University Hospitals to Present Results with Jvion's AI at HIMSS21


ATLANTA, July 27, 2021 /PRNewswire-PRWeb/ -- Jvion, a leader in clinical artificial intelligence (AI), will be featured prominently at HIMSS 2021 conference, to be held August 9-13 in Las Vegas, with results presented in two Essential Conversations. The sessions will demonstrate how healthcare organizations can use Jvion's clinical AI to integrate accurate and prescriptive intelligence into their clinical and operational workflows. In particular, Northwell Health realized a 23.6% reduction in readmissions, while University Hospitals improved resource allocation.

The first 60-minute Essential Conversation, "The Implementation of AI to Predict Ventilator Utilization," will be presented on August 11th at 11:45 AM by Dr. Maulik P. Purohit, MD, MPH, Associate Chief Medical Information Officer at University Hospitals, and Dr. John Frownfelter, MD, FACP, Chief Medical Officer at Jvion. The session will review the findings of a study to assess whether Jvion's clinical AI can accurately predict which patients were in need of ventilators in the ICU, which were in high demand at the peak of the pandemic. The session will also cover strategies for a successful AI implementation.

"The pandemic put immense strain on America's ICUs and forced clinicians to make life-or-death decisions in triaging their resources," said Dr. Frownfelter. "Our work with University Hospitals showed that AI can help care teams anticipate which patients can be safely discharged, which patients should be ventilated, and which patients are so at risk of dying that they would be best served by hospice care. In a surge, these insights can help ensure there are enough ventilators and ICU beds for the lives that depend on them."

"As clinicians, it's our job to make critical care decisions based on patient data, which can be challenging when resources are stretched thin and lives are on the line," said Dr. Purohit. "Our evaluation showed that clinical AI can recognize patterns in the data that wouldn't be obvious to a busy clinician or be flagged by traditional predictive analytics. This is an exciting time where we can provide better decision support leveraging the EMR data and potentially advance patient care tremendously."

On August 11th at 4:15 PM, Dr. Zenobia Brown, VP of Population Health and Medical Director at Northwell Health Solutions, and Hallie Bleau, AVP of Care Management & Transitional Care Management at Northwell Health, will present their Essential Conversation "Applying Clinical AI to Reduce Readmissions by Over 20%." In this discussion, the clinicians from Northwell Health, the largest healthcare provider in New York State, will share how they reduced readmissions by 23.6% by augmenting their post-discharge workflow with Jvion's prescriptive AI-powered insights.

"Under value-based care, reducing readmissions has become a major focus for health systems like Northwell," said Dr. Brown. "But it's not always easy to know which patients are vulnerable or what interventions will keep them from returning to the hospital. Prescriptive analytics allow us to see beyond the EHR to detect the social determinants of health that put patients at risk of readmission. Even more helpfully, it recommends personalized interventions based on its knowledge of what worked and what didn't for millions of patient journeys. It can be an incredibly valuable resource for case managers to have."

In addition to these conference presentations, representatives from Jvion will be on site to demonstrate its COREtm AI at the Innovaccer Partner Pavilion in booth 2461. Attendees are invited to schedule a consultation and a technology demo to learn more about how Jvion's AI-powered insights can empower care teams to better manage population health.

To schedule a meeting at HIMSS, please contact Jvion's Chief Marketing Officer Lizzy Feliciano at lizzy dot feliciano @ jvion dot com.

About Jvion
Jvion, a leader in clinical artificial intelligence, enables providers, payers and other healthcare entities to identify and prevent avoidable patient harm, utilization and costs. An industry first, the Jvion COREtm goes beyond predictive analytics and machine learning to identify patients on a trajectory to becoming high-risk. Jvion then determines the interventions that will more effectively reduce risk and enable clinical and operational action. The CORE accelerates time to value by leveraging established patient-level intelligence to drive engagement across healthcare organizations, populations and individuals. To date, the Jvion CORE has been deployed across hundreds of clients and resulted in millions saved. For more information, visit https://www.jvion.com.

Media Contact

Sara DeMoranville, Scratch Marketing + Media, (617) 945-9296, [email protected]

Twitter, Facebook

 

SOURCE Jvion


These press releases may also interest you

at 07:35
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives...

at 07:34
Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An," the "Company" or the "Group," HKEX: 2318; SSE: 601318) today announced its first quarter financial results for the three months ended March 31, 2024....

at 07:31
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an...

at 07:30
KFSH&RC participates as a strategic partner in the Saudi American Healthcare Forum, which will take place on April 25th under the patronage of the Ministry of Health in Riyadh. This forum aims to discuss the primary healthcare challenges facing the...

at 07:30
Factor Bioscience Inc., a Cambridge-based biotechnology company focused on...

at 07:15
Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today unveiled multiple pipeline programs ahead of the 27th ASGCT Annual meeting on May 7 - 11, 2024 in Baltimore, MD....



News published on and distributed by: